Outcome of Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome According to Health Insurance Status

Association between insurance status at diagnosis and overall survival in chronic myeloid leukemia: A population‐based study

“…However, in other studies of myelodysplastic syndromes, acute lymphoblastic leukemia, and acute myeloid leukemia, there was not a clear association between insurance status and outcomes. 14, 15 …”

“…13 However, in other studies of myelodysplastic syndromes, acute lymphoblastic leukemia, and acute myeloid leukemia, there was not a clear association between the insurance status and the outcomes. 14,15 One challenge with assessing the impact of disparities on acute leukemias is the heterogeneity of these diseases, which has substantial influence on the treatment response and patient survival. Chronic-phase CML, in contrast, is a relatively uniform disease characterized and defined by the Philadelphia chromosome, and there are highly effective therapies available to those who can afford them either on their own or through insurance or assistance programs.…”

“…[10][11][12] The impact of insurance status on outcomes has not been as clear in hematologic malignancies such as acute leukemia. [13][14][15] Moreover, to date, no such studies have specifically investigated CML, a malignancy for which access to therapy has a potentially high impact on outcomes because of the availability of highly effective and tolerable oral agents.…”

Insurance Status and Other Non-biological Factors Predict Outcomes in Acute Myelogenous Leukemia: Analysis of Data from the National Cancer Database

“…In a study from the 2002-2006 New York and California Cancer Registries, the researchers found no survival differences. However, the authors compared Medicaid patients with all other categories, including uninsured patients (44,45).…”

Clinicians and payers expect to wait and see before embracing CMS MIPS value pathways

“…Similarly, very few studies investigated insurance-related disparities in health outcomes based on race/ethnicity or on socioeconomic factors. 33,34 and 2 reported mixed findings. 35,36 All but one study reporting survival disparities were large retrospective registry studies, and overwhelmingly, they reported better survival among patients with insurance compared with those with no insurance and better survival among patients with private commercial insurance compared with other insurance types.…”